Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450

Drug Metabolism and Disposition

Volumn 27, Issue 12, 1999, Pages 1488-1495

  Erickson, David A ^a   Mather, Gary ^b,c   Trager, William F ^b   Levy, Rene H ^b   Keirns, James J ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CEDRA Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; ERYTHROMYCIN; KETOCONAZOLE; NEVIRAPINE; QUINIDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TROLEANDOMYCIN;

ARTICLE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; HUMAN; IN VITRO STUDY; LIVER MICROSOME; METABOLITE; PRIORITY JOURNAL;

ANTIBODIES; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; DRUG INTERACTIONS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; KETOCONAZOLE; MICROSOMES, LIVER; NEVIRAPINE; PHENOTYPE; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; TROLEANDOMYCIN;

EID: 0032727054     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Albengres E, Le Louet H and Tillement JP (1998) Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 18:83-97.
2. Boobis AR, Murry S, Hampden CE and Davies DS (1985) Genetic polymorphisms in drug oxidation: In vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities. Biochem Pharmacol 34:65-71.
3. Brian WR, Sari M-A. Iwasaki M, Shimada T, Kaminsky LS and Guengerich FP (1990) Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 29:280-292.
4. Bush ED, Low LK and Trager WF (1983) A sensitive and specific stable isotope assay for warfarin and its metabolites. Biomed Mass Spectrom 10:395-398.
5. Cheeseman SH, Havlir D, McLaughlin MM, Greenough TC, Sullivan JL, Hall D, Hattox SE, Spector SA, Stein DS, Myers M and Richman DD (1995) Phase 1/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J AIDS and Human Retrovirol 8:141-151.
6. Gelboin HV, Krausz KW, Goldfarb I, Buters JT, Yang SK, Gonzalez FJ, Korzekwa KR and Shou M (1995) Inhibitory and non-inhibitory monoclonal antibodies to human cytochrome P450 3A3/4. Biochem Pharmacol 50:1841-1850.
7. Goldstein JA, Faletto MB, Romkes-Sparks R, Sullivan T, Kitareewan S, Raucy JL, Lasker JM and Ghanayem BI (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans. Biochemistry 33:1743-1752.
8. Greenblatt DJ, Wright CE, von Moltke LL. Harmatz JS. Eherenberg BL, Barrel LM, Corbett K, Counihan M, Tobias S and Shader RI (1998) Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences. Clin Pharmacol Ther 64:237-247.
9. Guengerich FP (1994) Analysis and characterization of enzymes, in Principles and Methods of Toxicology (Hayes AW ed) pp 1259-1313, Raven Press Ltd., New York.
10. Hargrave KD. Proudfoot JR, Grozinger KG, Cullen E, Kapadia SR, Patel UR, Fuchs VU, Mauldin SC, Vitous J, Behnke ML, Klunder JM, Pal K, Skiles JW, McNeil DW, Rose JM, Chow GC, Skoog MT, Wu JC, Schmidt G, Engel WW, Eberlein WG, Saboe TD. Campbell SJ, Rosenthal AS and Adams J (1991) Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones J Med Chem 34:2231-2241.
11. Havlir D, Cheeseman SH, McLaughlin M, Murphey R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D, Myers M, Lamson M and Richman DD (1995) High-dose nevirapine: Safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 171:537-545.
12. Klunder JM, Hoermann M, Cywin CL, David E, Brickwood JR, Schwartz R, Barringer KJ , Pauletti D, Shih C-K, Erickson DA, Sorge CL, Joseph DP, Hattox SE, Adams J and Grob PM (1998) Novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 7. 8-Arylethyl-dipyridodiazepinones as potent broad-spectrum inhibitors of wild-type and mutant enzymes, J Med Chem 41:2960-2971.
13. Kronbach T, Mathys D, Catin T and Meyer UA (1987) High-performance liquid Chromatographic assays for bufuralol 1'-hydroxylase and dextromethorphan O-dememylation in microsomes and purified cytochrome P450 isozymes of human liver. Anal Biochem 162:24-32.
14. Lamson MJ, Cort S, Sabo JP, MacGregor TR and Keirns JJ (1995) Effects of gender on the single and multiple dose pharmacokinetics of NVP 200 mg/day. Pharmaceut Res 12:S-101.
15. Lowry OH, Rosenbrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
16. Merry C, Barry MG, Mulcahy F, Ryan M, Heavey J. Tija JF. Gibbons SE, Breckenfidge AM and Back DJ (1997) Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11:F29-F33.
17. Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA and Wolf CR (1990) Identification of human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity, Biochem J 267:365-371.
18. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin FJ, Gonzalez FJ and Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59.
19. Riska P, Lamson M, MacGregor T, Sabo J, Hattox S. Pav J and Keirns J (1999) Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 27: 895-901.
20. Spinler SA, Cheng JW, Kindwall KE and Charland (1995) Possible inhibition of hepatic metabolism of quinidine by erythromycin. Clin Pharmacol Ther 57:89-94.
21. Tassaneeyakul W, Veronese ME, Birkett DJ, Gonzalez FJ and Miners JO (1993a) Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem Pharmacol 46:1975-1981.
22. Tassaneeyakul W, Veronese ME, Birkett DJ and Miners JO (1993b) High-performance liquid Chromatographic assay for 4-nitrophenol hydroxylation, a putative cytochrome P-4502E1 activity, in human liver microsomes. J Chromatogr 616:73-78.
23. Thummel KE, Kharasch ED, Podoll T and Kunze K (1993) Human liver rnicrosomal enflurane defluorination catalysed by P-450 2E1. Drug Metab Dispos 21:350-357.
24. Van Cleef GF, Fisher EJ and Polk RE (1997) Drug interaction potential with inhibitors of HIV protease. Pharmacotherapy 17:774-778.
25. Wrighton SA, Stevens JC, Becker GW and VandenBranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch Biochem Biophys 306:1-6.
26. Yamazaki H, Guo Z, Pensmark M, Mimura M, Inoue K, Guengerich FP and Shimada T (1994) Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Mol Pharmacol 46:568-577.
27. Zylber-Katz E (1995) Multiple drug interactions with cyclosporine in a heart transplant patient. Ann Pharmacother 19:127-131.